The South European Uroncological Group has conducted a phase III trial comparing intermittent androgen deprivation with continuous therapy in patients with advanced prostate cancer. The intermittent regimen was found to be non-inferior in terms of disease progression, survival, and quality of life. Nevertheless, the implications of such research for patient management remain controversial.